Startseite » Publications

Publications i-Target

Original Papers


Doctoral students of i-Target are marked in blueproject leaders in black, associated doctoral students (otherwise funded) in grey.



26. Rataj F, Jacobi S, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha B, van Puijenbroek E, Heise C, Düwell P, Endres S, Klein Ch, Kobold S.
High affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy.
Br J Cancer 2019; 120:79-87
JIF 6.2


25. Jitschin R, Saul D, Braun M, Tohumeken S, Völkl S, Kischel R, Lutteropp M, Dos Santos C, Mackensen A, Mougiakakos D.
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells.
J Immunother Cancer; 2018, 6:116

24. Keppler SJ, Burbage M, Gasparrini F, Hartjes L, Aggarwal S, Massaad MJ, Geha RS, Bruckbauer A, Batista FD.
The Lack of WIP Binding to Actin Results in Impaired B Cell Migration and Altered Humoral Immune Responses.
Cell Rep. 2018; 24:619-629

23. Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Blood 2018; 132:2484-2494

22. Rataj F, Kraus F, Chaloupka M, Grassmann S, Heise C, Cadilha B, Duewell P, Endres S, Kobold S.
PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin-lymphoma.
Front Immunol 2018; 9:1955
JIF 6.4

21. Weidenbusch M, Song S, Iwakura T, Shi C, Rodler S, Kobold S, Mulay SR, Honarpisheh MM, Anders HJ.
IL-22 sustains epithelial integrity in progressive kidney remodeling and fibrosis.
Physiol Rep. 2018; 6:e13817

20. Andrade L, Tay R, Pan D, Luoma A, Ito Y, Badrinath S, Tsoucas D, Franz B, May K, Harvey Ch, Kobold S, Pyrdol J, Yoon Ch, Yuan G, Hodi S, Dranoff G, Wucherpfennig K.
Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity.
Science 2018359:1537-1542.
JIF 35.3

19. Damby D, Horwell C, Baxter P, Kueppers U, Schnurr M, Dingwell D, Duewell P.
Volcanic ash activates the NLRP3 inflammasome in murine and human macrophages.
Front Immunol 2018; 8:2000
JIF 6.4

18. Metzger PKirchleitner S, König L, Hörth Ch, Kobold SEndres SSchnurr MDuewell P.
Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies.
Science Reports 2018; 8
JIF 4.8


17. Makanyengo RDuewell PReichl C, Hörth Ch, Lehr HA, Fischer S, Clavel T, Denk G, Hohenester S, Kobold SEndres SSchnurr M, Bauer Ch.

Nlrp3-dependent IL-1ß inhibits CD103+ dendritic cell differentiation in the gut.
JCI Insight 2018; 3
JIF (available summer 2019)


16. Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M.
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Frontiers in Immunology 2018; 9:385.
JIF 5.5


15. Loschinski R, Böttcher M, Stoll A, Bruns H, Mackensen A, Mougiakakos D.
IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner.
Oncotarget. 2018; 9(17): 13125-13138




14. Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT,  Arendt KAM, Heise C, Rataj F, Janssen KP, Königshofff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S and Kobold S.
Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.
PNAS USA 2017; 114(49):12994-12999
JIF 9.6
* contributed equally to this study


13. Wennhold K, Thelen M, Schlößer HA, Haustein N, Reuter S, Garcia-Marquez M, Lechner A, Kobold S, Rataj F, Utermöhlen O, Chakupurakal G, Theurich S, Hallek M, Abken H, Shimabukuro-Vornhagen A, von Bergwelt-Baildon M.
Using antigen-specific B cells to combine antibody and T cell-based cancer immunotherapy.
Cancer Immunology Research 2017; 5(9):730-743
JIF 8.2


12. Cadilha B, Dormann K, Rataj F, Endres S and Kobold S.
Enabling T cell recruitment to tumours as a strategy for improving adoptive T cell therapy. 
European Oncology and Hematology 2017; 13:66-73


11. Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe MHopfner KP.
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Oncotarget 2017; 8(7):11284-11301
JIF 5.0




10. Groß CJ, Mishra R, Schneider KS, Médard G, Wettmarshausen J, Dittlein DC, Shi H, Gorka O, König PA, Fromm S, Magnani G, Ćiković T, Hartjes L, Smollich J, Robertson AAB, Cooper MA, Schmidt-Supprian M, Schuster M, Schroder K, Broz P, Traidl-Hoffmann C, Beutler B, Kuster B, Ruland J, Schneider S, Perocchi F, Groß O.
K+ efflux-independent NLRP3 inflammasome activation by a small molecule targeting mitochondria.
Immunity 2016; 45:1-13.
JIF 24.1


9. Qorraj M, Bruns H, Böttcher M, Weigand L, Saul D, Mackensen A, Jitschin R, Mougiakakos D.
The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
Leukemia 2016; doi:10.1038/leu.2016.214.
JIF 12.1


8.Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Rataj F, Janssen KP, Endres S, Anz D, Kobold S.
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer.
Oncoimmunology 2016; 5:e1105428.
JIF 7.3


7. Roskopf C, Braciak TA, Fenn NC, Kobold S, Fey GH, Hopfner KP, Oduncu FS.
Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells.
Oncotarget 2016; 7:22579-22589.
JIF 5.0


6. Wiedemann G, Jacobi SChaloupka M, Hamm S, Strobl S, Baumgartner R,Rothenfusser S, Duewell P, Endres SKobold S.
A novel TLR7 agonist reverses NK cell anergy and cures RMA-S lymphoma-bearing mice.
Oncoimmunology 2016; 5:e1189051.
JIF 7.3


5. Schiller CB, Braciak TA, Fenn NC, Seidel UJE, Roskopf C, Wildenhain S, Honegger A, Schubert IA, Schele A, Lämmermann K, Fey GH, Jacob U, Lang P, Hopfner KP, Oduncu FS.
CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B lymphoid cells.
Oncotarget; 7:83392-83408.
JIF 5.0




4. Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger JC, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner G, Klein C, Bourquin C, Endres S.
Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer.
The Journal of the National Cancer Institute 2015; 107:364.
JIF 15.2


3. Kobold S*, Grassmann S*, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#.
Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy.
The Journal of the National Cancer Institute 2015; 107: djv146.
JIF 15.2

* contributed equally to this study, # share senior authorship


2. Ernst A, Anders H, Kapfhammer H, Orth M, Hennel R, Seidl K, Winssinger N, Belka C, Unkel S, Lauber K.
HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas.
Cancer Letters 2015; 365:211-222.
JIF 5.0


1. Duewell P, Beller E, Kirchleitner S, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold SEndres SSchnurr M.
Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma.
Oncoimmunology 2015; 4: e1029698.
JIF 6.3


B Reviews



7. Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K.
Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.
Immunological Reviews 2017; 280:249-279




6. Bauer C, Kühnemuth B, Düwell P, Ormanns S, Gress T, Schnurr M.
Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer.
Cancer Letters 2016; 381:259-268.
JIF 6.0




5. Weidenbusch M, Rodler S, Anders HJ.
Interleukin-22 in kidney injury and regeneration.
American Journal of Physiology - Renal Physiologogy 2015; 308:F041-1046.
JIF 3.2


4. Lauber K, Brix N, Ernst A, Hennel R, Krombach J, Anders H, Belka C.
Targeting the heat shock response in combination with radiotherapy: Sensitizing cancer cells to irradiation-induced cell death and heating up their immunogenicity.
Cancer Letters 2015; 15:162-167.
JIF 5.0 


3. Schnurr MDüwell P, Bauer C, Rothenfusser S, Lauber KEndres SKobold S.
Strategies to relieve immunosuppression in pancreatic cancer.
Immunotherapy 2015; 7:363-376.
JIF 2.4


2. Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Immunotherapy of tumors – Activated T cells as a new treatment modality.
Deutsches Ärzteblatt International 2015; 112:809-15.
JIF 3.7




1. Kobold S, Wiedemann G, Rothenfusser S, Endres S.
Modes of action of TLR7 agonists in cancer therapy.
Immunotherapy 2014; 6:1085-95.
JIF 2.4